The name change to QTREX Quantum and pivot toward quantum connectivity/AME is a narrative rebranding with no attached financial data. Monitor for subsequent filings (contracts, revenue guidance, funding rounds) to assess whether the strategic pivot gains commercial traction. The existing medical device legacy and monetization efforts remain unquantified. The low market cap ($4M) and poor historical call performance (11% T+20 win rate) suggest high noise and limited institutional following -- trade cautiously on thin liquidity.
Price Chart
Executive Summary
Inspira Technologies Oxy B.H.N. Ltd. (IINN/IINNW) has changed its corporate name to Qtrex Quantum Ltd. and will begin trading under the new ticker symbols QTEX/QTEXW on May 20, 2026, following shareholder approval. The name change reflects a strategic pivot from its legacy medical device focus toward an Additively Manufactured Electronics (AME) platform targeting quantum computing connectivity infrastructure. No financial terms, shareholder rights changes, or operational metrics were disclosed.
Key Facts
- Shareholders approved name change on May 6, 2026; effective with Israeli Registrar on May 10, 2026.
- New ticker QTEX (common) and QTEXW (warrants) start trading on Nasdaq on May 20, 2026.
- Company pivots strategic focus from medical devices to AME platform for quantum connectivity, defense, and aerospace applications.
- No financial figures, revenue, EPS, or deal values provided in the filing.
- CUSIP unchanged; no shareholder action required.
- Company continues to hold medical tech portfolio and is 'actively working to monetize certain parts of the medical business.'
- Form 20-F for FY2025 filed Mar 26, 2026 shows 35,949,247 ordinary shares outstanding as of Dec 31, 2025.
Financial Impact
No financial terms disclosed; purely administrative name change and ticker symbol update.
Risk Factors
- No revenue or product milestones disclosed for the new AME/quantum focus -- purely forward-looking statements.
- Company has a history of poor stock performance (avg -22.95% T+20 across 9 prior settled reports) despite bullish framing.
- Potential liquidity issues given $4M market cap and pivot requiring significant R&D investment.
- Monetization of legacy medical assets may be dilutive or value-destructive.
- Warrant overhang (IINNW/QTEXW) adds complexity and potential dilution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001185185-26-001910 |
| Document: iinn6k051926.htm | 0001185185-26-001910 |
| Document: iinnex99-1.htm | 0001185185-26-001910 |
| Document: 0001185185-26-001910-index-headers.html | 0001185185-26-001910 |
| Document: 0001185185-26-001910-index.html | 0001185185-26-001910 |
| Document: 0001185185-26-001910.txt | 0001185185-26-001910 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 19w ago | 6-K | $0.1420 $0.1200 | ▼ −15.49% | ▼ −16.48% | — |
May 18, 2026 19w ago | 6-K | $0.0830 $0.1310 | ▲ +57.83% | ▲ +56.25% | — |
Apr 16, 2026 24w ago | 6-K | $0.1100 $0.0690 | ▼ −37.27% | ▼ −43.09% | — |
Apr 16, 2026 24w ago | 6-K | $0.1100 $0.0690 | ▼ −37.27% | ▼ −43.09% | — |
Apr 15, 2026 24w ago | 6-K | $0.1100 $0.0690 | ▼ −37.27% | ▼ −43.09% | — |
Apr 14, 2026 24w ago | 6-K | $0.0720 $0.0690 | ▼ −4.17% | ▼ −10.46% | — |
Apr 13, 2026 24w ago | 6-K | $0.0600 $0.0690 | ▲ +15.00% | ▲ +7.27% | — |
Apr 6, 2026 25w ago | 6-K | $0.1000 $0.0680 | ▼ −32.00% | ▼ −40.98% | — |
Apr 6, 2026 25w ago | 6-K | $0.1000 $0.0680 | ▼ −32.00% | ▼ −40.98% | — |
Mar 31, 2026 26w ago | 6-K | $0.0800 $0.0690 | ▼ −13.75% | ▼ −23.17% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access